Status:
COMPLETED
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
Lead Sponsor:
Organon and Co
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.
Eligibility Criteria
Inclusion
- Male and female subjects age 18 to 75 with a confirmed clinical diagnosis of plaque psoriasis and stable disease for at least 6 months prior to the study
- BSA involvement ≥ 20%
- PGA score of ≥ 3 at screening
- Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study
- Capable of giving written informed consent
Exclusion
- Psoriasis other than plaque variant
- Any sign of infection of any of the psoriatic lesions
- Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory abnormality that will affect the health of the subject or interfere with the interpretation of the results
- Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 4 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's psoriasis
- Use of any prohibited medication within the indicated period before the first dose of study drug
- Pregnant females or lactating females
- The subject has received an investigational product within 30 days, 5 half-lives, or twice the duration of the biological effect of the study drug (whichever is longer) prior to first dose of study drug
- Current or a history of cancer within 5 years except for fully excised skin basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
- Previous known participation in a clinical study with tapinarof
Key Trial Info
Start Date :
July 23 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 9 2020
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04042103
Start Date
July 23 2019
End Date
January 9 2020
Last Update
June 19 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermavant Investigational Site
Encino, California, United States, 91436
2
Dermavant Investigational Site
Sanford, Florida, United States, 32771
3
Dermavant Investigational Site
Philadelphia, Pennsylvania, United States, 19103
4
Dermavant Investigational Site
Austin, Texas, United States, 78759